Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Privia Health (PRVA) Cash & Equivalents (2020 - 2025)

Privia Health (PRVA) has 6 years of Cash & Equivalents data on record, last reported at $479.7 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 2.33% year-over-year to $479.7 million; the TTM value through Dec 2025 reached $479.7 million, down 2.33%, while the annual FY2025 figure was $479.7 million, 2.33% down from the prior year.
  • Cash & Equivalents reached $479.7 million in Q4 2025 per PRVA's latest filing, up from $441.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $491.1 million in Q4 2024 and bottomed at $81.9 million in Q1 2021.
  • Average Cash & Equivalents over 5 years is $355.9 million, with a median of $349.6 million recorded in 2022.
  • The widest YoY moves for Cash & Equivalents: up 285.57% in 2022, down 12.49% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $320.6 million in 2021, then rose by 8.55% to $348.0 million in 2022, then grew by 11.93% to $389.5 million in 2023, then grew by 26.09% to $491.1 million in 2024, then fell by 2.33% to $479.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $479.7 million in Q4 2025, $441.4 million in Q3 2025, and $390.1 million in Q2 2025.